Trials / Completed
CompletedNCT01626573
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itacitinib | |
| DRUG | Itacitinib Placebo |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-07-01
- Completion
- 2013-10-01
- First posted
- 2012-06-22
- Last updated
- 2019-03-12
Locations
18 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01626573. Inclusion in this directory is not an endorsement.